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Rationale: The peptide bombesin (BBN) and its derivatives exhibit high binding afﬁnity for the gastrin-
releasing peptide receptor (GRPR), which is highly expressed in prostate cancer. We used the BBN-based
radiopharmaceutical 99mTechnetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) (99mTc-HABBN) to perform
a ﬁrst-in-man clinical pilot study to evaluate the feasibility of 99mTc-HABBN SPECT/CT for detection of prostate
cancer in patients.
Methods: Eight patients with biopsy-proven prostate cancer who were scheduled for either radical
prostatectomy or external beam radiotherapy underwent 99mTc-HABBN scintigraphy and SPECT/CT prior to
treatment. Serial blood samples were taken to assess blood radioactivity and to determine in vivo metabolic
stability. Clinical parameters were measured and reported side effects, if present, were recorded. Prostate
cancer specimens of all patients were immunohistochemically stained for GRPR.
Results: 99mTc-HABBN was synthesized with high radiochemical yield, purity and speciﬁc activity. There were
no signiﬁcant changes in clinical parameters, and there were no adverse or subjective side effects. Low
metabolic stability was observed, as less than 20% of 99mTc-HABBN was intact after 30 min. Immunohisto-
chemical staining for GRPR was observed in the prostate cancer specimens in all patients. 99mTc-HABBN
scintigraphy and SPECT/CT did not detect prostate cancer in patients with proven disease.
Conclusions: 99mTc-HABBN SPECT/CT for visualization of prostate cancer is safe but hampered by an
unexpected low in vivo metabolic stability in man. The difference between the excellent in vitro stability
of 99mTc-HABBN in human serum samples determined in our previous study regarding 99mTc-HABBN and
the low in vivo metabolic stability determined in this study, is striking. This issue warrants further study
of peptide-based radiopharmaceuticals.
© 2013 Elsevier Inc. All rights reserved.ﬁnancial relationship with the
conﬂict of interest.
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Prostate cancer is one of the most common causes of cancer in
males and is a common cause of morbidity and death worldwide [1].
Early detection of prostate cancer may lead to an improved cure rate.
An increased level of prostate-speciﬁc antigen (PSA) in serum or a
palpable prostatic nodule found with digital rectal examination raises
the suspicion of prostate cancer and necessitates transrectal ultra-
sound-guided biopsies of the prostate for histological diagnosis.
934 H.J.K. Ananias et al. / Nuclear Medicine and Biology 40 (2013) 933–938Although performing transrectal ultrasound-guided biopsies is the
gold standard procedure, it has certain drawbacks, such as the chance
of under- or overstaging due to sampling error in multifocal disease
[2]. Furthermore, transrectal ultrasound-guided biopsies have a
suboptimal sensitivity, as they can miss up to 35% of cancers [3–5].
A negative (repeat) biopsy, despite a persistently elevated PSA, poses
a diagnostic dilemma [6,7].
An imaging technique that is sufﬁciently sensitive to detect
prostate cancer and/or sufﬁciently speciﬁc to exclude cancer is
necessary. In addition to detection and local staging of prostate
cancer, other possible uses of such an imaging technique could be the
guidance for prostate biopsies, application of intensity-modulated
radiotherapy on hot-spots, detection of distant metastases or local
recurrence and therapy response monitoring.
Nuclear imaging techniques such as single photon emission
computed tomography (SPECT) and positron emission tomography
(PET) have emerged as promising diagnostic tools in oncology [8–10].
Of the available radiopharmaceuticals for prostate cancer detection,
18F PET/CT and 11C-choline PET/CT are mostly used in centers all
worldwide, as they are currently the best-performing nuclear imaging
techniques. However, the limited sensitivity for small-sized metasta-
ses, relatively low uptake of choline at low PSA levels and uptake of
choline in normal or inﬂamed prostate limit the accuracy of choline
PET/CT in staging prostate cancer [10,11]. Therefore, crucial for
accurate new nuclear imaging techniques is the development of
radiopharmaceuticals that can be targeted to speciﬁc tumor-associ-
ated antigens, which are over-expressed in prostate cancer but are
sparse in normal tissues.
A tumor-associated antigen that is of particular interest is the
gastrin-releasing peptide receptor (GRPR). GRPR is over-expressed in
various human malignancies, including primary and metastatic
prostate cancer [12,13]. Importantly, GRPR expression in normal
tissue ranges from absent to low [14–17], making GRPR an excellent
target for high-contrast imaging. The mammalian ligand for GRPR
and its amphibian counterpart bombesin (BBN) share an identical
seven-amino-acid carboxyl-terminal region, and both possess the
same afﬁnity for GRPR. However, BBN has been shown to be
signiﬁcantly more stable, and a series of BBN analogs has been
constructed and labeled with various radionuclides (i.e., 99mTc, 111In,
64Cu, 18F) [18,19].
Recently, we reported the synthesis of 99mTc-HYNIC(tricine/
TPPTS)-Aca-BBN(7–14) (from here on: 99mTc-HABBN; HYNIC = 6-
hydrazinonicotinic acid; TPPTS = trisodium triphenylphosphine-
3,3′,3″-trisulfonate; Aca = ε-Amino-caproic acid) and its promising
results as an imaging agent in a xenograft tumor model for human
prostate cancer in athymic mice [20].
The aim of the study described in this report was to perform a ﬁrst-
in-man clinical pilot study to evaluate the feasibility of 99mTc-HABBN
SPECT/CT for detection of prostate cancer in patients.
2. Material and methods
2.1. Chemicals, materials and equipment
Na99mTcO4 was eluted from the 99Mo/99mTc generator (Ultra-
Technekow; Covidien, Petten, The Netherlands). Succinic acid and
tricine (N-(Tri(hydroxymethyl)methyl)glycine) were purchased from
Sigma/Aldrich (St. Louis, MO, USA). TPPTS was purchased from Alfa
Aesar (Karlsruhe, Germany). The peptide Aca-BBN(7–14) was
provided by Peptides International (Louisville, KY, USA). HYNIC-
Aca-BBN(7–14) was synthesized as reported previously [20]. For
sterilization, a 0.22-μm Millex GV-ﬁlter (Merck Millipore, Billerica,
MA, USA) was used. High-performance liquid chromatography
(HPLC) was performed using a HITACHI L-2130 HPLC system (Hitachi
High Technologies America Inc., Pleasanton, CA, USA). Isolation of
radiolabeled peptides was performed using a Phenomenex reversed-phase Luna C18 column (Phenomenex, Torrance, CA, USA). The Sep-
Pak C18 light cartridge was from Waters Corporation (Milford, MA,
USA). Radioactivity of samples was measured in a γ-counter
(Compugamma CS1282; LKB-Wallac, Turku, Finland).
For immunohistochemistry experiments, PC-3 human prostate
cancer xenograft tumors (ATCC, Manassas, VA, USA), normal goat
serum, 0.05% 3,3′-diaminobenzidine, Eukitt mounting medium, 1% AB
serum (Sigma-Aldrich, St. Louis, MO, USA), hematoxylin (Merck,
Whitehouse Station, NJ, USA), anti-human-GRPR rabbit polyclonal
antibody ab39963 (Abcam, Cambridge, UK) and goat anti-rabbit
antibody P0448 (Dako, Glostrup, Denmark) were used.
2.2. Preparation of 99mTc-HABBN
Synthesis of 99mTc-HABBN was performed as described previously
[20] under GMP conditions with modiﬁcations. All solutions (except
the HYNIC-Aca-BBN(7–14) and the SnCl2 solution) were sterilized
before use by passing through a 0.22-μm Millex GV-ﬁlter under
aseptic conditions (class A) in a cleanroom. Brieﬂy, 99mTc-pertechne-
tate solution (~2.8 GBq in saline, ~2 mL) was collected in a sterile vial
(5 mL). 50 μL of HYNIC-Aca-BBN(7–14) (1 mg/mL in sterile water),
100 μL of tricine solution (100 mg/mL in 25 mM succinate buffer,
pH 5.0), 100 μL of TPPTS solution (50 mg/mL in 25 mM succinate
buffer, pH 5.0) and 15 μL of SnCl2 (1.0 mg/mL inwater) were added to
the vial and well mixed. The pH value (pH 5.0) of the mixture was
checked with pH paper, and then the mixture was incubated at 95 °C
for 20 min. A needle connected to a 0.22-μm Millex GV-ﬁlter was
placed in the cap of the vial to avoid overpressure and contamination.
After cooling to room temperature, the reactionmixturewaspuriﬁed
with semi-preparative reversed-phase HPLC column equipped with a
UV detector (wave length = 218 nm) and a radioactivity detector.
Isolation of 99mTc-HABBN was performed using a Phenomenex
reversed-phase Luna C18 column (10 mm × 250 mm, 5 μm) with a
ﬂow rate at 2.5 mL/min. A gradient system was applied for isolation
of 99mTc-HABBN, starting from 90% solvent A (0.01 M phosphate
buffer with 0.1 mg/mL ascorbic acid (AA), pH = 6.0) and 10% solvent
B (acetonitrile (ACN) with 0.1 mg/mL AA) (5 min) and ramped to
45% solvent A and 55% solvent B at 35 min.
The 99mTc-HABBN eluate from the HPLC system was diluted with
saline with 1% AA (10 mL) before loading on a Sep-PAK C18 light
cartridge. The C18 cartridge was washed with saline with 1% AA
(50 mL) and eluted with EtOH (400 μL) afterwards. The EtOH
solution was diluted with saline solution (with 1% AA; limit:
~10 mL) and was sterilized by passing through a 0.22-μm GV-ﬁlter.
A quantity of 550–700 MBq was dispensed in a syringe under aseptic
conditions (class A).
2.3. Quality control of 99mTc-HABBN
Before release of the ﬁnal product, the integrity of the 0.22-μm
Millex GV ﬁlter (used for sterilization of the ﬁnal product) was
determined using the bubble point test, and the radiochemical purity
of the ﬁnal product was determined by analyzing a 5-MBq portion
using HPLC. After release, the sterility test was performed by keeping
two samples (100 μL) of the ﬁnal product in two bottles of Clausen
medium at 25 °C and 37 °C for 1 week. The remaining product was
used for the pyrogenicity test, the residual solvents test and the EtOH
concentration test performed at the Pharmacy Department of the
University Medical Center Groningen after decay.
2.4. Patient recruitment
The present study was approved by the Medical Ethics Committee
of the University Medical Center Groningen and was performed
according to Good Clinical Practice guidelines.
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scheduled for laparoscopic radical prostatectomy (RP), and four
planned for external beam radiotherapy (EBRT)) were recruited on
the outpatient clinic of the department of Urology at the University
Medical Center Groningen, after providing written informed consent.
The pre-therapy PSA level, prostate volume as determined by
transrectal ultrasound, tumor stage (according to the 1997 TNM
staging criteria), results of prostate histology (either via whole
prostatectomy specimens or prostate biopsies; Gleason sum score, %
tumor volume) and results of pelvic lymph node dissection (1/4 in the
RP group, 4/4 in the EBRT group) were recorded.
2.5. Scintigraphy, SPECT/CT and image analysis
SPECT/CT scanning was performed before EBRT or 1 day before
surgery. Subjects were positioned supine with their arms outstretched
in holders, and a venous cannula was placed in both forearms—left for
injection of the radiopharmaceutical and right for blood sampling. For
low-dose computed tomography, the arms were positioned above the
head. Images of the pelvis were performed using a Siemens Symbia T2
double headed gamma camera, equipped with low-energy, high-
resolution collimators, combined with an integrated 2-slice computed
tomography. To acquire quantitative results, a sample of 99mTc of
known activity (20–28 MBq) was scanned along with the patient.
Different data acquisition protocols were used to acquire an optimal
time-point for scanning. Patients 1–4 were subjected to a dynamic
scanning protocol with the gamma camera heads in the anterior–
posterior (AP) position, 1 min per frame during 20 min, starting
immediately after 99mTc-HABBN injection (549–688 MBq). Thereafter,
a 2 × 180° SPECT of the pelvic regionwas performedwith amatrix size
of 128 × 128 in 64 positions and an acquisition time of 40 s per
position. Next, a low-dose CT of the pelvis was performed (110 kV,
30 mA). At 2, 4, 6 and 20 h post-injection (p.i.), SPECT was performed
again at the 20 h-time-point combinedwith low-dose CT. Patient 5was
subjected to a dynamic scan for 120 minwith the gamma camera in the
AP position at 1 min per frame during the ﬁrst hour and 2 min per
frameduring the secondhour. At 4, 6 and 20 hp.i., a static scan in the AP
positionwasmade for 10, 30 and 30 min, respectively. In patients 6–8, a
dynamic scan was made for 60 min, 1 min per frame, followed by
SPECT/CT and single-frame, 30-min static images at 2, 4 and 6 h p.i.
Additionally, in patients 3, 4, 6, 7 and 8, a transurethral catheter was
inserted to drain the bladder and reduce local radioactivity.
Images were reconstructed using iterative reconstruction (Flash
3D, 8 iterations, 16 subsets, Gaussian 9.0 ﬁlter). In addition to
anatomical localization, CT was also used to obtain an attenuation
map. Dynamic and static images were displayed in coronal planes, and
SPECT imageswere displayed in transaxial, coronal and sagittal planes.
The tumor to normal tissue ratioswere determined by placing a region
of interest (ROI) over the area showing the most activity in the tumor
and an identically sized ROI over the gluteal muscles. Image analysis
and subjective assessment were performed by a nuclear physician (JP)
blinded to patient data and 1 non-blinded researcher (HA).
2.6. Monitoring of vital parameters and side effects
Because this was a ﬁrst-in-man study, the heart rate, oxygen
saturation and blood pressure were monitored in all patients during
the ﬁrst hour p.i. at regular intervals (0, 5, 10, 15, 20, 25, 30, 45 and
60 min) and were compared with baseline measurements before
injection of 99mTc-HABBN. Side effects, if reported by the patient
within 24 h p.i., were documented.
2.7. Analysis of radioactivity in blood samples
Blood samples (2 mL/time point) were collected from six patients
via a venous cannula in the right forearm at 0, 2, 5, 10, 30, 60, 120, 240,360 and 1200 min (the last time point was not analyzed for patients 7
and 8) p.i. of 99mTc-HABBN. No blood sampling of patients 2 and 6 was
performed due to technical failure.
Blood serum samples were acquired by centrifuging the blood
sample at 3000 rpm for 5 min. For each sample, the radioactivity of full
blood and blood serum (250 μL), as well as the original 99mTc-HABBN
saline solution (10 μL in triplicate) was determined in a γ-counter. The
radioactivity accumulation of 99mTc-HABBN in full blood and serumwas
calculated as follows: counts of the 250-μL sample *4 / total injected
counts (percentage of the injected dose/mL, mean ± SD, n = 6).
2.8. Metabolic stability of 99mTc-HABBN
The in vivo metabolic stability of 99mTc-HABBN was determined
by analyzing blood serum samples collected at 0 (baseline), 2, 5, 10,
30, 60 and 120 min p.i. of 99mTc-HABBN from patients 1, 3, 4 and 5.
Blood serum samples were acquired as described above. The protein
of blood serum samples was removed by centrifuging at 3000 rpm
for 5 min after mixing with a 10-fold volume of ACN. The
supernatant was passed through a Sep-Pak C18 light cartridge and
eluted with water (5 mL) and EtOH (2 mL). The radioactivity of the
eluents was determined in a γ-counter. The percentage of metabo-
lites was calculated as follows: (aqueous eluent radioactivity /
(aqueous eluent radioactivity + EtOH eluent radioactivity)) * 100%
(mean ± SD, n = 4).
2.9. Immunohistochemical staining of GRPR
In patients scheduled for RP, prostatectomy specimens were used
for immunohistochemical staining of GRPR. In patients who did not
undergo RP, prostate biopsy specimens were used.
Formalin-ﬁxed, parafﬁn-embedded blocks of prostate cancer
tissue were cut into 3-μm thick sections and mounted on APES
(3-aminopropyltriethoxysilane)-coated slides. A human prostate
cancer PC-3 xenograft tumor was used as the positive control. As
the negative control, the primary antibody was omitted during
immunohistochemical analysis on the positive control tissue. Tris-
buffered saline (TBS) was used for washing and dilution of
antibodies. After deparafﬁnization, antigen retrieval was per-
formed by microwave heating (400 W) for 20 min in a 0.1 M
Tris/HCl buffer at pH 9.0. Endogenous peroxidase was blocked by
incubation with 0.3% hydrogen peroxide in TBS for 20 min. To
decrease non-speciﬁc background staining, slides were incubated
with normal goat serum diluted at 1:10 in TBS for 30 min at
room temperature.
Tissue section slides were incubated with primary anti-human-
GRPR rabbit polyclonal antibody ab39963 diluted at 1:250 in 1%
bovine serum albumin (BSA)/TBS overnight at 4 °C. A secondary
step with goat anti-rabbit antibody P0448 diluted at 1:100 in 1%
BSA/TBS with 1% AB serum was applied for 60 min at room
temperature. Slides were immersed for 10 min in a solution of
0.05% 3,3′-diaminobenzidine and 0.03% hydrogen peroxide in TBS
for visualization of the signal as brown staining. After washing with
demineralized water, slides were counterstained with hematoxylin
and dehydrated. Finally, a coverslip was applied using Eukitt
mounting medium.
2.10. Assessment of GRPR staining
An experienced pathologist (SR) blinded to the clinical data
scored the staining intensity (0 = no staining, 1+ = weak stain-
ing, 2+ = moderate staining, 3+ = strong staining) of tumor
areas for all specimens. Specimens, in which one or more tumor
areas with different staining intensities were present, were scored
for the most prevalent intensity.
Table 1
Release and post-release speciﬁcations for 99mTc-HABBN.
99mTc-HABBN Speciﬁcation Required
before release
Frequency
Appearance Clear,
colorless
Yes Every synthesis
pH 5–8 Yes Every synthesis
Radiochemical purity (%) N95% Yes Every synthesis
Speciﬁc activity (MBq/mg) N5000 Yes Every synthesis
Bubble point test
sterilization ﬁlter
b20% Yes Every synthesis
Sterility Sterile No Every synthesis
Endotoxins (EU/mL) b0.25 No Every synthesis
EtOH concentration (g/L) b100 No Every synthesis
ACN concentration (mg/L) b50 No Every synthesis
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3.1. Synthesis and quality control of 99mTc-HABBN
99mTc-HABBNwas prepared (n = 8) with a radiochemical yield of
43% ± 4%, a speciﬁc activity of 87.2 ± 9.4 TBq/mmol and a radio-
chemical purity of 97.3% ± 0.9%. The bubble point test of the
sterilization ﬁlter was performed before the injection of 99mTc-
HABBN. The sterility, endotoxin and residual solvents tests were
performed after release of the radiotracer. The ﬁnal product was
sterile and apyrogenic (b0.25 EU/mL), and residual solvents were
found to be b50 mg/L and b100 g/L for ACN and EtOH, respectively.
Release and post-release speciﬁcations are summarized in Table 1.
3.2. Patient characteristics
Details of included patients and results of histology can be found in
Table 2. Although initially selected for EBRT, patients 7 and 8 proved
to have lymph node metastases and were subsequently selected for
hormonal therapy.
3.3. Image analysis
Thorough analysis of the dynamic, static and SPECT images
with or without CT by one dedicated nuclear medicine physician
(JP) blinded to patient data and one non-blinded researcher (HA),
revealed no uptake of radioactivity in the prostate or pelvic
lymph nodes (histologically proven lymph node metastases in
patients 7 and 8). Rapid distribution via blood was observed, and
excretion via urine was observed within 5–7 min. The transure-
thral catheter reduced radioactivity in the pelvis, improving
visualization of tissue in the immediate vicinity of the bladder.
The procedure did not lead to detection of a hot-spot in theTable 2
Patient characteristics.
Pt. nr. Age PSA PrV Therapy
1 59 5,9 35 RP
2 55 16 21 RP
3 69 12 47 RP
4 73 7,8 56 EBRT
5 55 15,5 23 RP
6 73 69.8 38 EBRT
7 71 221.5 55 HT
8 70 23.8 39 HT
Biopsy results are not displayed when histology of a radical prostatectomy is available. In EBR
PSA in ng/mL, PrV = prostate volume in mL, RP = radical prostatectomy, EBRT = externa
TumorV = % tumor volume (tumor volume based on prostate biopsies are presented as follo
volume), Gl = Gleason sum score, PLND = pelvic lymph node dissection, np = not perfor
a Based on histology of radical prostatectomy specimens, b Based on digital rectal examprostate. Furthermore, no hot-spots outside the bladder or
prostate were observed in the pelvis. No ROIs were drawn
because the tumor was not visualized.
3.4. Monitoring of vital parameters and side effects
In the ﬁrst hour after 99mTc-HABBN injection, vital parameters
(heart rate, oxygen saturation and blood pressure) were measured at
regular intervals andwere comparedwith baselinemeasurements. No
clinically signiﬁcant changes in the heart rate (N15% change), oxygen
saturation (N5% change) and blood pressure (N15% change) were
recorded. None of the patients suffered from adverse or subjective
side effects.
3.5. Analysis of radioactivity in blood
Fig. 1 shows the full blood and serum radioactivity curves after 99mTc-
HABBN injections in patients during the 1200-min study period (n = 6,
except at the 1200-min time point where n = 4). A steady decline of the
radioactivity was observed in blood and serum during the experimental
period. The radioactivity level became almost undetectable at 20 h p.i.
3.6. Metabolic stability of 99mTc-HABBN
Fig. 2 shows the in vivo degradation of 99mTc-HABBN. There are
low metabolic stability and rapid degradation of 99mTc-HABBN, with
22%, 44% and 53% of the radioactivity degradedwithin 2, 5 and 10 min
p.i., respectively. After 30 min, less than 20% of 99mTc-HABBN was
still intact.
3.7. Assessment of immunohistochemical GRPR staining
Immunohistochemistry on parafﬁn slides of prostate cancer
specimens (four whole prostate sections, four prostate needle biopsy
specimens) demonstrated low-to-moderate staining of prostate
cancer for GRPR in 8/8 cases (Table 3).
4. Discussion
Targeted imaging could improve the lack of accuracy observed in
current imaging techniques used in different stages of prostate cancer.
Recently, we have developed the novel BBN-based radiopharmaceu-
tical, designated 99mTc-HABBN, and evaluated its imaging potential in
a xenograftmousemodel of humanprostate cancer [20]. The aimof the
study presented here was to perform a ﬁrst-in-man clinical pilot study
to evaluate the feasibility of 99mTc-HABBN SPECT/CT for detection of
prostate cancer in patients. We were able to synthesize a radiophar-
maceutical with high yield, speciﬁc activity and purity, in the absence
of any signs of adverse or subjective side effects after patientT-stage TumorV Gl PLND
pT2ca 5%a 7a np
pT2ca N50%a 6a np
pT2ca b50%a 7a pN0
cT1cb Left/5/5/75%, Right/5/1/5%c 7c pN0
pT3aa N50%, capsular penetration lefta 8a np
cT2cb Left/5/2/15%, Right/5/4/45%c 9c pN0
cT3b Left/4/4/65%, Right/4/4/10%c 7c pN1
cT2cb Left/4/4/35%, Right/4/4/20%c 7c pN1
T or hormonal therapy patients, only prostate biopsy histology is available. Age in years,
l beam radiotherapy, HT = hormonal therapy, T-stage = tumor stage.
ws: side/biopsy cores taken on that side/number of positive cores on that side/%tumor
med, pN0 = no pelvic lymph node metastases, pN1 = pelvic lymph node metastases.
ination and histology of prostate biopsies, c Based on histology of prostate biopsies.
Fig. 1. Full blood and serum activity curves during the 1200-min study. Values are expressed as the percentage of the injected dose per mL (%ID/mL, mean ± SD, n = 6, except at the
1200-min time point where n = 4).
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did not detect prostate cancer in patients with proven disease.
Although immediate distribution via the vascular system and rapid
excretion via the renal route were deduced from the dynamic images,
nouptake in theprostatewas observedat any timepoint in anypatient.
Although bladder drainage using a transurethral catheter proved to be
helpful in reducing activity in the bladder with an improved ability to
assess pelvic organs, it did not aid in detecting hot-spots.
Because small tumors could be missed with SPECT, patients with
larger tumor volumes and higher PSA values were selected in the
second half of the patient inclusion (patients 5–8). The different
patient selection sorted no effect. Additionally, there has been some
discussion concerning the level of GRPR expression according to
various Gleason sum scores. Although this could not be proven in
lymph node and bone metastases of prostate cancer [12], Beer et al.
demonstrated that a higher Gleason sum score tends to express lower
levels of GRPR [13]. Therefore, a range of Gleason sum scores was
selected (Gleason 6–9; lower scores are seldomobserved, and Gleason
10 is only rarely eligible for local therapy), but did not give other
results with 99mTc-HABBN scintigraphy and SPECT/CT. One reason for
the failure to visualize the prostate tumors is that, by chance, GRPR
expression in 8 prostate cancer patients could be absent. However,
with immunohistochemistry on parafﬁn slides of the prostate cancer0 30 60 90 120
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Fig. 2. The in vivo metabolic stability of 99mTc-HABBN. Results are plotted as the
percentage of formed metabolites at different time points (mean ± SD, n = 4). At the
120-min time point, the SD is too small to display.specimens of these patients, we proved the presence of GRPR in all our
patients (Table 3). Although immunohistochemistry shows the
presence and tissue distribution of an antigen, the technique cannot
demonstrate absolute antigen density and is therefore not a strong
predictor for uptake of a GRPR-targeting radiopharmaceutical.
The difference between the in vitro stability in human serum samples
determined in our previous study on 99mTc-HABBN [20] and the in vivo
metabolic stability determined in the present study, is striking. In our
previous study, we have demonstrated that 77% of 99mTc-HABBN is intact
after 24 h in human serum in vitro [20]. However, the results of the
current study indicate that metabolites are formed as early as 10 min p.i.
and that less than 20% of 99mTc-HABBN is intact after 30 min. Thus, we
must conclude that one of themain reasons for the failure to visualize the
prostate tumors is the rapid in vivo degradation of 99mTc-HABBN (Fig. 2).
Similar results were observed in a study by Linder et al., where the
metabolism of 177Lu-AMBA inmice and rats in vivowasmuchmore rapid
than that in vitro [21].
Rapid and highly selective proteolytic cleavage of bioactive
peptides is not unexpected because this is key in the autonomic
regulation of the biologic effects of peptides. It is unknown which
enzymes are responsible for the degradation of BBN in vivo. In this
respect, ecto-enzymes located on the cell surface that shed in blood
and are highly expressed in the liver and kidneys could be major
players in this process [22]. Therefore, to more accurately determine
radiochemical stability, it was suggested by Ocak et al. to use liver and
kidney homogenates [23]. By contrast, in another study by the same
author, it was shown that rat liver and kidney homogenates were not
good predictors for in vivo stability [24].
In a pre-clinical study in a xenograft tumor model for human
prostate cancer in athymic mice, we have demonstrated moderate
uptake of 99mTc-HABBN in tumors [20]. Moderate uptake in tumorsTable 3
Staining intensities of the antibodies used in prostate cancer specimens.
Patient number Pathology Staining intensity
1 Radical prostatectomy +
2 Radical prostatectomy +
3 Radical prostatectomy +
4 Prostate needle biopsy +
5 Radical prostatectomy +
6 Prostate needle biopsy +
7 Prostate needle biopsy ++
8 Prostate needle biopsy +
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low to create high tumor-to-background ratios and excellent contrast.
Performance of a BBN-like radiopharmaceutical in a pre-clinical
mouse model is not a strong predictor for clinical performance in
humans because there is a different body biodistribution of GRPR in
mice compared with humans. Nevertheless, the moderate uptake
of 99mTc-HABBN in tumor cells as previously demonstrated in the pre-
clinical study could be another contributing factor leading to failure to
visualize the prostate tumors in prostate cancer patients in this study.
Other clinical studies in prostate cancer patients with BBN-like
radiopharmaceuticals have shown fairly good results [19]. A study by
Scopinaro et al. is particularly interesting because high uptake in the
prostate was found in all eight prostate cancer patients, and pathology-
conﬁrmed invasion in obturator nodes was found in three of these
patients [26]. Despite the clinical results of other groups and theﬁndings
of our pre-clinical studywhere theprostate tumorwas clearly visualized
in mice with 99mTc-HABBN microSPECT, we could not detect prostate
cancer with 99mTc-HABBN scintigraphy and SPECT/CT in patients of the
current clinical study. Two main reasons for the inability to detect
prostate cancer with scintigraphy and SPECT/CT are most likely the low
in vivo stability of 99mTc-HABBN resulting in low-circulating intact
radiopeptide and the absolute tumor uptake of 99mTc-HABBN being too
low because of the relatively low to moderate expression of GRPR in
primary prostate cancer. When considering the IC50, the in vivo tumor
uptake and tumor-to-normal-tissue ratios in the pre-clinical study, the
afﬁnity and performance of 99mTc-HABBN are essentially similar
compared with other BBN analogs reported in the literature [19,25].
The pre-clinical data of the BBN-like radiopharmaceuticals that have
been used for imaging of prostate cancer patients are not available in the
international literature and, therefore, cannot be compared with our
pre-clinical data.
The ﬁndings that the in vitro stability of a BBN-like radiopharma-
ceutical in human serum does not correlate with in vivo stability and
that the in vivo performance of a BBN-like radiopharmaceutical in a
mouse tumor model does not correlate with in vivo performance in
man are interesting. As demonstrated previously, determination of
the stability of a radiolabeled peptide in vitro in serum has no
predictive value for its in vivo stability in rodents [21,23,24]. The
development of new or improved in vitro stability tests or better pre-
clinical in vivo tumor models may prove to be a better approach for
selecting radiolabeled peptides of appropriate stability and afﬁnity for
clinical testing. Future studies should focus on developing high-
afﬁnity BBN-like radiopharmaceuticals that have been proven to be
highly stable in a pre-clinical setting. Additionally, instead of using the
relatively low-resolution SPECT for imaging, the use of radiopeptides
suitable for PET imaging will aid in improvement of imaging.
5. Conclusions
99mTechnetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7–14)
SPECT/CT for the detection of prostate cancer is safe but is hampered
by an unexpectedly low in vivo metabolic stability in man. The
difference between the excellent in vitro stability in human serum
determined in our previous study on 99mTc-HABBN and the low in vivo
metabolic stability determined in the present study is striking.
Furthermore, the current study showed that the in vivo performance
in a mouse tumor model does not correlate with in vivo performance
in prostate cancer patients. This issue warrants further study of
peptide-based radiopharmaceuticals.
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